Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients

Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Oncogenesis (New York, NY) Ročník 13; číslo 1; s. 26 - 10
Hlavní autoři:	van Harten, Anne M., Shah, Ronak, de Boer, D. Vicky, Buijze, Marijke, Kreft, Maaike, Song, Ji-Ying, Zürcher, Lisa M., Jacobs, Heinz, Brakenhoff, Ruud H.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 11.07.2024 Nature Publishing Group
Témata:	13 13/100 13/106 13/109 13/31 13/51 13/89 14 14/1 14/34 14/56 38 42 45 631/154/1438 631/154/555 631/154/556 631/208/68 631/67/1536 82 82/80 Anemia Apoptosis Breast cancer Cell Biology Chemoradiotherapy Chemotherapy Cisplatin DNA repair Fanconi syndrome Gemcitabine Genetic screening Head & neck cancer Head and neck carcinoma Hemopoiesis Hereditary diseases Human Genetics Internal Medicine Malignancy Medicine Medicine & Public Health Nucleotide analogs Oncology Patients Radiation therapy Ribonucleotide reductase siRNA Squamous cell carcinoma Therapeutic targets Toxicity Tumor cell lines
ISSN:	2157-9024, 2157-9024
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of developing malignancies early in life, in particular head and neck squamous cell carcinoma (HNSCC). While ICL-inducing cisplatin combined with radiotherapy is a mainstay of HNSCC treatment, cisplatin is contra-indicated for FA-HNSCC patients. This dilemma necessitates the identification of novel treatment modalities tolerated by FA-HNSCC patients. To identify druggable targets, an siRNA-based genetic screen was previously performed in HNSCC-derived cell lines from FA and non-FA tumor origin. Here, we report that the Ribonucleotide Reductase (RNR) complex, consisting of the RRM1 and RRM2 subunits, was identified as a therapeutic target for both, FA and non-FA HNSCC. While non-FA HNSCC cells responded differentially to RNR depletion, FA-HNSCC cells were consistently found hypersensitive. This insight was confirmed pharmacologically using 2′, 2′-difluoro 2′deoxycytidine (dFdC), also known as gemcitabine, a clinically used nucleotide analog that is a potent inhibitor of the RNR complex. Importantly, while cisplatin exposure displayed severe, long-lasting toxicity on the hematopoietic stem and progenitor compartments in Fancg−/− mice, gemcitabine was well tolerated and had only a mild, transient impact. Taken together, our data implicate that gemcitabine-based chemoradiotherapy could serve as an alternative HNSCC treatment in Fanconi patients, and deserves clinical testing.
AbstractList	Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of developing malignancies early in life, in particular head and neck squamous cell carcinoma (HNSCC). While ICL-inducing cisplatin combined with radiotherapy is a mainstay of HNSCC treatment, cisplatin is contra-indicated for FA-HNSCC patients. This dilemma necessitates the identification of novel treatment modalities tolerated by FA-HNSCC patients. To identify druggable targets, an siRNA-based genetic screen was previously performed in HNSCC-derived cell lines from FA and non-FA tumor origin. Here, we report that the Ribonucleotide Reductase (RNR) complex, consisting of the RRM1 and RRM2 subunits, was identified as a therapeutic target for both, FA and non-FA HNSCC. While non-FA HNSCC cells responded differentially to RNR depletion, FA-HNSCC cells were consistently found hypersensitive. This insight was confirmed pharmacologically using 2′, 2′-difluoro 2′deoxycytidine (dFdC), also known as gemcitabine, a clinically used nucleotide analog that is a potent inhibitor of the RNR complex. Importantly, while cisplatin exposure displayed severe, long-lasting toxicity on the hematopoietic stem and progenitor compartments in Fancg−/− mice, gemcitabine was well tolerated and had only a mild, transient impact. Taken together, our data implicate that gemcitabine-based chemoradiotherapy could serve as an alternative HNSCC treatment in Fanconi patients, and deserves clinical testing. Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of developing malignancies early in life, in particular head and neck squamous cell carcinoma (HNSCC). While ICL-inducing cisplatin combined with radiotherapy is a mainstay of HNSCC treatment, cisplatin is contra-indicated for FA-HNSCC patients. This dilemma necessitates the identification of novel treatment modalities tolerated by FA-HNSCC patients. To identify druggable targets, an siRNA-based genetic screen was previously performed in HNSCC-derived cell lines from FA and non-FA tumor origin. Here, we report that the Ribonucleotide Reductase (RNR) complex, consisting of the RRM1 and RRM2 subunits, was identified as a therapeutic target for both, FA and non-FA HNSCC. While non-FA HNSCC cells responded differentially to RNR depletion, FA-HNSCC cells were consistently found hypersensitive. This insight was confirmed pharmacologically using 2', 2'-difluoro 2'deoxycytidine (dFdC), also known as gemcitabine, a clinically used nucleotide analog that is a potent inhibitor of the RNR complex. Importantly, while cisplatin exposure displayed severe, long-lasting toxicity on the hematopoietic stem and progenitor compartments in Fancg-/- mice, gemcitabine was well tolerated and had only a mild, transient impact. Taken together, our data implicate that gemcitabine-based chemoradiotherapy could serve as an alternative HNSCC treatment in Fanconi patients, and deserves clinical testing. Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of developing malignancies early in life, in particular head and neck squamous cell carcinoma (HNSCC). While ICL-inducing cisplatin combined with radiotherapy is a mainstay of HNSCC treatment, cisplatin is contra-indicated for FA-HNSCC patients. This dilemma necessitates the identification of novel treatment modalities tolerated by FA-HNSCC patients. To identify druggable targets, an siRNA-based genetic screen was previously performed in HNSCC-derived cell lines from FA and non-FA tumor origin. Here, we report that the Ribonucleotide Reductase (RNR) complex, consisting of the RRM1 and RRM2 subunits, was identified as a therapeutic target for both, FA and non-FA HNSCC. While non-FA HNSCC cells responded differentially to RNR depletion, FA-HNSCC cells were consistently found hypersensitive. This insight was confirmed pharmacologically using 2', 2'-difluoro 2'deoxycytidine (dFdC), also known as gemcitabine, a clinically used nucleotide analog that is a potent inhibitor of the RNR complex. Importantly, while cisplatin exposure displayed severe, long-lasting toxicity on the hematopoietic stem and progenitor compartments in Fancg-/- mice, gemcitabine was well tolerated and had only a mild, transient impact. Taken together, our data implicate that gemcitabine-based chemoradiotherapy could serve as an alternative HNSCC treatment in Fanconi patients, and deserves clinical testing.Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of developing malignancies early in life, in particular head and neck squamous cell carcinoma (HNSCC). While ICL-inducing cisplatin combined with radiotherapy is a mainstay of HNSCC treatment, cisplatin is contra-indicated for FA-HNSCC patients. This dilemma necessitates the identification of novel treatment modalities tolerated by FA-HNSCC patients. To identify druggable targets, an siRNA-based genetic screen was previously performed in HNSCC-derived cell lines from FA and non-FA tumor origin. Here, we report that the Ribonucleotide Reductase (RNR) complex, consisting of the RRM1 and RRM2 subunits, was identified as a therapeutic target for both, FA and non-FA HNSCC. While non-FA HNSCC cells responded differentially to RNR depletion, FA-HNSCC cells were consistently found hypersensitive. This insight was confirmed pharmacologically using 2', 2'-difluoro 2'deoxycytidine (dFdC), also known as gemcitabine, a clinically used nucleotide analog that is a potent inhibitor of the RNR complex. Importantly, while cisplatin exposure displayed severe, long-lasting toxicity on the hematopoietic stem and progenitor compartments in Fancg-/- mice, gemcitabine was well tolerated and had only a mild, transient impact. Taken together, our data implicate that gemcitabine-based chemoradiotherapy could serve as an alternative HNSCC treatment in Fanconi patients, and deserves clinical testing. Abstract Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of developing malignancies early in life, in particular head and neck squamous cell carcinoma (HNSCC). While ICL-inducing cisplatin combined with radiotherapy is a mainstay of HNSCC treatment, cisplatin is contra-indicated for FA-HNSCC patients. This dilemma necessitates the identification of novel treatment modalities tolerated by FA-HNSCC patients. To identify druggable targets, an siRNA-based genetic screen was previously performed in HNSCC-derived cell lines from FA and non-FA tumor origin. Here, we report that the Ribonucleotide Reductase (RNR) complex, consisting of the RRM1 and RRM2 subunits, was identified as a therapeutic target for both, FA and non-FA HNSCC. While non-FA HNSCC cells responded differentially to RNR depletion, FA-HNSCC cells were consistently found hypersensitive. This insight was confirmed pharmacologically using 2′, 2′-difluoro 2′deoxycytidine (dFdC), also known as gemcitabine, a clinically used nucleotide analog that is a potent inhibitor of the RNR complex. Importantly, while cisplatin exposure displayed severe, long-lasting toxicity on the hematopoietic stem and progenitor compartments in Fancg−/− mice, gemcitabine was well tolerated and had only a mild, transient impact. Taken together, our data implicate that gemcitabine-based chemoradiotherapy could serve as an alternative HNSCC treatment in Fanconi patients, and deserves clinical testing. Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA interstrand crosslinks (ICLs). The disease is characterized by congenital abnormalities, progressing bone marrow failure, and an increased risk of developing malignancies early in life, in particular head and neck squamous cell carcinoma (HNSCC). While ICL-inducing cisplatin combined with radiotherapy is a mainstay of HNSCC treatment, cisplatin is contra-indicated for FA-HNSCC patients. This dilemma necessitates the identification of novel treatment modalities tolerated by FA-HNSCC patients. To identify druggable targets, an siRNA-based genetic screen was previously performed in HNSCC-derived cell lines from FA and non-FA tumor origin. Here, we report that the Ribonucleotide Reductase (RNR) complex, consisting of the RRM1 and RRM2 subunits, was identified as a therapeutic target for both, FA and non-FA HNSCC. While non-FA HNSCC cells responded differentially to RNR depletion, FA-HNSCC cells were consistently found hypersensitive. This insight was confirmed pharmacologically using 2′, 2′-difluoro 2′deoxycytidine (dFdC), also known as gemcitabine, a clinically used nucleotide analog that is a potent inhibitor of the RNR complex. Importantly, while cisplatin exposure displayed severe, long-lasting toxicity on the hematopoietic stem and progenitor compartments in Fancg−/− mice, gemcitabine was well tolerated and had only a mild, transient impact. Taken together, our data implicate that gemcitabine-based chemoradiotherapy could serve as an alternative HNSCC treatment in Fanconi patients, and deserves clinical testing.
ArticleNumber	26
Author	van Harten, Anne M. de Boer, D. Vicky Buijze, Marijke Brakenhoff, Ruud H. Shah, Ronak Kreft, Maaike Jacobs, Heinz Song, Ji-Ying Zürcher, Lisa M.
Author_xml	– sequence: 1 givenname: Anne M. orcidid: 0000-0002-8528-6997 surname: van Harten fullname: van Harten, Anne M. organization: Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Biology & Immunology Section, Cancer Center Amsterdam, Cancer Biology and Immunology – sequence: 2 givenname: Ronak surname: Shah fullname: Shah, Ronak organization: Division of Tumor Biology & Immunology, The Netherlands Cancer Institute – sequence: 3 givenname: D. Vicky surname: de Boer fullname: de Boer, D. Vicky organization: Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Biology & Immunology Section, Cancer Center Amsterdam, Cancer Biology and Immunology – sequence: 4 givenname: Marijke surname: Buijze fullname: Buijze, Marijke organization: Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Biology & Immunology Section, Cancer Center Amsterdam, Cancer Biology and Immunology – sequence: 5 givenname: Maaike surname: Kreft fullname: Kreft, Maaike organization: Division of Tumor Biology & Immunology, The Netherlands Cancer Institute – sequence: 6 givenname: Ji-Ying surname: Song fullname: Song, Ji-Ying organization: Department of Experimental Animal Pathology, The Netherlands Cancer Institute – sequence: 7 givenname: Lisa M. surname: Zürcher fullname: Zürcher, Lisa M. organization: Division of Tumor Biology & Immunology, The Netherlands Cancer Institute – sequence: 8 givenname: Heinz orcidid: 0000-0001-6227-9850 surname: Jacobs fullname: Jacobs, Heinz organization: Division of Tumor Biology & Immunology, The Netherlands Cancer Institute – sequence: 9 givenname: Ruud H. orcidid: 0000-0003-3251-5378 surname: Brakenhoff fullname: Brakenhoff, Ruud H. email: rh.brakenhoff@amsterdamumc.nl organization: Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Biology & Immunology Section, Cancer Center Amsterdam, Cancer Biology and Immunology
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38992100$$D View this record in MEDLINE/PubMed
BookMark	eNp9kUtv1TAQhS1URB_0D7BAltiwCfiROPYSVfQhVbCBtTVxxr2-JPbFzl303-PblIK6qDe2xt85nvE5JUcxRSTkHWefOJP6c2m51KZhom0Y60TXiFfkRPCub0ytHf13PibnpWxZXZ3iquvekOOqNIIzdkK-XeHswgJDiEihULfBOS0bzLC7p8nTDcJIIY40ovtFHUSHmYZIL-spxVCvcA5Ad7AEjEt5S157mAqeP-5n5Ofl1x8X183t96ubiy-3jWt1tzTcgFBiZOPgVSfasdfGy3rjOBvk4MWAIKTvWud7x4VXaPjAwEsNGsdBgzwjN6vvmGBrdznMkO9tgmAfCinfWchLcBNakL1TynlwEttRKoOd0NXZMNUaN7jq9XH12uX0e49lsXMoDqepzpb2xUrWG95zpVVFPzxDt2mfY530QGktq7Wp1PtHaj_MOD619_fXKyBWwOVUSkb_hHBmD-naNV1b07MP6VpRRfqZ6JDbElJcMoTpZalcpaW-E-8w_2v7BdUf4U63Gg
CitedBy_id	crossref_primary_10_1615_CritRevEukaryotGeneExpr_2024057000
Cites_doi	10.1038/sj.bjc.6603860 10.1016/S0140-6736(18)32752-1 10.1038/nrc3916 10.1002/hed.23004 10.1182/blood-2002-07-2170 10.1158/1541-7786.MCR-18-0445 10.1016/j.oraloncology.2013.03.446 10.1016/j.mrfmmm.2009.01.013 10.1038/s41572-020-00224-3 10.1038/nrclinonc.2010.16 10.1002/hed.26395 10.1055/s-0032-1308989 10.1016/j.bbmt.2018.08.028 10.1002/jcc.20054 10.1002/hed.25577 10.1158/1078-0432.CCR-17-0263 10.1016/j.trecan.2017.10.005 10.1038/onc.2014.155 10.1097/CCO.0b013e3280f01010 10.1001/jamaoto.2022.2791 10.1097/JTO.0b013e318165c170 10.1016/j.critrevonc.2018.02.013 10.1002/chem.200700260 10.3390/cancers13112774 10.1093/jnci/djn366 10.1158/1078-0432.CCR-21-1259 10.1016/j.radonc.2009.04.014 10.1038/s41467-021-26472-9 10.1016/j.cub.2017.07.043 10.1093/nar/gkac545 10.1038/nature10192 10.1016/S0140-6736(18)32779-X 10.1093/annonc/mdh071 10.1182/blood-2002-05-1498 10.1038/nrc.2017.116 10.1038/nrc.2018.11 10.1002/lary.25726 10.1016/j.oraloncology.2019.09.004 10.1186/s40348-014-0009-8 10.1186/s12943-022-01695-6 10.18632/oncotarget.17880 10.1038/s41598-020-58509-2
ContentType	Journal Article
Copyright	The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION NPM 3V. 7X7 7XB 88A 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 DOA
DOI	10.1038/s41389-024-00525-2
DatabaseName	Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	PubMed MEDLINE - Academic CrossRef Publicly Available Content Database
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	2157-9024
EndPage	10
ExternalDocumentID	oai_doaj_org_article_a37c66cfac3e4d369e5284cf90649cbc 38992100 10_1038_s41389_024_00525_2
Genre	Journal Article
GrantInformation_xml	– fundername: KWF Kankerbestrijding (Dutch Cancer Society) grantid: 10032; 10796 funderid: https://doi.org/10.13039/501100004622 – fundername: KWF Kankerbestrijding (Dutch Cancer Society) grantid: 10796 – fundername: KWF Kankerbestrijding (Dutch Cancer Society) grantid: 10032
GroupedDBID	0R~ 3V. 53G 5VS 7X7 88A 88I 8FE 8FH 8FI 8FJ AAJSJ ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV AENEX AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBLON EBS FYUFA GNUQQ GROUPED_DOAJ HCIFZ HMCUK HYE KQ8 LK8 M0L M2P M7P M~E NAO OK1 PGMZT PIMPY PQQKQ PROAC RNT RNTTT RPM SNYQT UKHRP AASML AAYXX CITATION M48 NPM PHGZT 7XB 8FK K9. PHGZM PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO
ID	FETCH-LOGICAL-c485t-19a262d0dbf6524d789f3485c10b3bf2bea23f54cf7c12f6e91b0af38a8edb8a3
IEDL.DBID	BENPR
ISICitedReferencesCount	0
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001269120200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2157-9024
IngestDate	Tue Oct 14 18:59:43 EDT 2025 Thu Oct 02 06:59:02 EDT 2025 Sat Nov 29 14:48:29 EST 2025 Thu Apr 03 07:08:11 EDT 2025 Sat Nov 29 02:53:40 EST 2025 Tue Nov 18 19:49:03 EST 2025 Fri Feb 21 02:40:43 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	2024. The Author(s).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c485t-19a262d0dbf6524d789f3485c10b3bf2bea23f54cf7c12f6e91b0af38a8edb8a3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0001-6227-9850 0000-0003-3251-5378 0000-0002-8528-6997
OpenAccessLink	https://www.proquest.com/docview/3078835289?pq-origsite=%requestingapplication%
PMID	38992100
PQID	3078835289
PQPubID	2041913
PageCount	10
ParticipantIDs	doaj_primary_oai_doaj_org_article_a37c66cfac3e4d369e5284cf90649cbc proquest_miscellaneous_3079171686 proquest_journals_3078835289 pubmed_primary_38992100 crossref_primary_10_1038_s41389_024_00525_2 crossref_citationtrail_10_1038_s41389_024_00525_2 springer_journals_10_1038_s41389_024_00525_2
PublicationCentury	2000
PublicationDate	2024-07-11
PublicationDateYYYYMMDD	2024-07-11
PublicationDate_xml	– month: 07 year: 2024 text: 2024-07-11 day: 11
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: United States – name: New York
PublicationTitle	Oncogenesis (New York, NY)
PublicationTitleAbbrev	Oncogenesis
PublicationTitleAlternate	Oncogenesis
PublicationYear	2024
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	McGregor, Wagner, Felix, Soutar, Parkinson, Harrison (CR44) 1997; 57 Heinemann, Xu, Chubb, Sen, Hertel, Grindey (CR19) 1990; 38 Pereira, Fernandes, Ramos (CR20) 2004; 25 Van Zeeburg, Snijders, Wu, Gluckman, Soulier, Surralles (CR46) 2008; 100 Kutler, Patel, Auerbach, Kennedy, Lach, Sanborn (CR8) 2016; 126 Nagel, Martens-de Kemp, Buijze, Jacobs, Braakhuis, Brakenhoff (CR48) 2013; 49 Aye, Li, Long, Weiss (CR15) 2015; 34 Huang, Chubb, Hertel, Grindey, Plunkett (CR18) 1991; 51 CR2 Johnson, Burtness, Leemans, Lui, Bauman, Grandis (CR38) 2020; 6 Bourhis, Le Maître, Baujat, Audry, Pignon (CR29) 2007; 19 Lee, Kang, Yom, Smogorzewska, Johnson, Grandis (CR5) 2021; 27 Van Zeeburg, Graveland, Brink, Nguyen, Leemans, Bloemena (CR42) 2013; 35 Lewis, Tang, Wise-Draper, Myers, Greenberger, Takiar (CR37) 2020; 42 Aguilar-Ponce, Granados-García, Villavicencio, Poitevin-Chacón, Green, Dueñas-González (CR33) 2004; 15 CR47 Braakhuis, van Dongen, Vermorken, Snow (CR24) 1991; 51 Gillison, Trotti, Harris, Eisbruch, Harari, Adelstein (CR35) 2019; 393 Beckham, Leeman, Jillian Tsai, Riaz, Sherman, Singh (CR36) 2019; 41 Ueno, Kiyosawa, Kaniwa (CR31) 2007; 97 Vos, Elbers, Krijgsman, Traets, Qiao, van der Leun (CR39) 2021; 12 McGregor, Muntoni, Fleming, Brown, Felix, MacDonald (CR45) 2002; 62 Dudek, Chereddy, Nguyen, Wagner, Maddaus (CR41) 2008; 3 Fernandes, Ramos (CR21) 2007; 13 Rosenberg, Greene, Alter (CR4) 2003; 101 Furquim, Pivovar, Amenábar, Bonfim, Torres-Pereira (CR11) 2018; 125 de Boer, Brink, Buijze, Stigter-van Walsum, Hunter, Ylstra (CR43) 2018; 17 Langevin, Crossan, Rosado, Arends, Patel (CR9) 2011; 475 Mahieu, Mancini, Vikram, Planells-Palop, Joseph, Tward (CR32) 2023; 22 Spanjaard, Shah, de Groot, Buoninfante, Morris, Lieftink (CR25) 2022; 50 CR14 Sagawa, Ohguchi, Harada, Samur, Tai, Munshi (CR16) 2017; 23 de Boer, Martens-de Kemp, Buijze, Stigter-Walsum Van, Bloemena, Dietrich (CR49) 2017; 8 Heinemann, Hertel, Grindey, Plunkett (CR17) 1988; 48 Auerbach (CR12) 2009; 668 Nepal, Che, Zhang, Ma, Fei (CR27) 2017; 3 Mehanna, Robinson, Hartley, Kong, Foran, Fulton-Lieuw (CR34) 2019; 393 Nalepa, Clapp (CR6) 2018; 18 Rodríguez, D’Andrea (CR1) 2017; 27 Scheckenbach, Wagenmann, Freund, Schipper, Hanenberg (CR3) 2012; 224 van Harten, Brakenhoff (CR30) 2021; 13 CR23 Sun, Candelieri-Surette, Anglin-Foote, Lynch, Maxwell, D’Avella (CR10) 2022; 148 Gaillard, García-Muse, Aguilera (CR22) 2015; 15 Pignon, Maître, Maillard, Bourhis (CR28) 2009; 92 Ijaz, Khan, Malik, Faridi, Fraz, Usman (CR40) 2019; 25 Berlin, Benson III (CR26) 2010; 7 Leemans, Snijders, Brakenhoff (CR7) 2018; 18 Kutler, Singh, Satagopan, Batish, Berwick, Giampietro (CR13) 2003; 101 HJT Van Zeeburg (525_CR42) 2013; 35 PA Fernandes (525_CR21) 2007; 13 TH Beckham (525_CR36) 2019; 41 V Heinemann (525_CR17) 1988; 48 525_CR2 CR Leemans (525_CR7) 2018; 18 HJT Van Zeeburg (525_CR46) 2008; 100 H Ueno (525_CR31) 2007; 97 525_CR14 DV de Boer (525_CR43) 2018; 17 R Nagel (525_CR48) 2013; 49 CP Furquim (525_CR11) 2018; 125 G Nalepa (525_CR6) 2018; 18 DI Kutler (525_CR13) 2003; 101 S Pereira (525_CR20) 2004; 25 F McGregor (525_CR44) 1997; 57 JL Vos (525_CR39) 2021; 12 DE Johnson (525_CR38) 2020; 6 L Sun (525_CR10) 2022; 148 A Ijaz (525_CR40) 2019; 25 525_CR47 AD Auerbach (525_CR12) 2009; 668 LM Lewis (525_CR37) 2020; 42 DI Kutler (525_CR8) 2016; 126 F Langevin (525_CR9) 2011; 475 P Huang (525_CR18) 1991; 51 AM van Harten (525_CR30) 2021; 13 H Gaillard (525_CR22) 2015; 15 BJ Braakhuis (525_CR24) 1991; 51 A Rodríguez (525_CR1) 2017; 27 ML Gillison (525_CR35) 2019; 393 K Scheckenbach (525_CR3) 2012; 224 Y Aye (525_CR15) 2015; 34 DV de Boer (525_CR49) 2017; 8 CI Mahieu (525_CR32) 2023; 22 A Spanjaard (525_CR25) 2022; 50 J Berlin (525_CR26) 2010; 7 JL Aguilar-Ponce (525_CR33) 2004; 15 M Nepal (525_CR27) 2017; 3 M Sagawa (525_CR16) 2017; 23 RH Lee (525_CR5) 2021; 27 J Bourhis (525_CR29) 2007; 19 525_CR23 PS Rosenberg (525_CR4) 2003; 101 JP Pignon (525_CR28) 2009; 92 V Heinemann (525_CR19) 1990; 38 H Mehanna (525_CR34) 2019; 393 AZ Dudek (525_CR41) 2008; 3 F McGregor (525_CR45) 2002; 62
References_xml	– volume: 51 start-page: 6110 year: 1991 end-page: 7 ident: CR18 article-title: Action of 2’,2’-difluorodeoxycytidine on DNA synthesis publication-title: Cancer Res – volume: 97 start-page: 145 year: 2007 ident: CR31 article-title: Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603860 – volume: 393 start-page: 51 year: 2019 end-page: 60 ident: CR34 article-title: Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)32752-1 – volume: 15 start-page: 276 year: 2015 end-page: 80 ident: CR22 article-title: Replication stress and cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc3916 – volume: 35 start-page: 568 year: 2013 end-page: 74 ident: CR42 article-title: Generation of precursor cell lines from preneoplastic fields surrounding head and neck cancers publication-title: Head Neck doi: 10.1002/hed.23004 – volume: 48 start-page: 4024 year: 1988 end-page: 31 ident: CR17 article-title: Comparison of the cellular pharmacokinetics and toxicity of 2’,2’-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine publication-title: Cancer Res – volume: 101 start-page: 1249 year: 2003 end-page: 56 ident: CR13 article-title: A 20-year perspective on the International Fanconi Anemia Registry (IFAR) publication-title: Blood doi: 10.1182/blood-2002-07-2170 – volume: 51 start-page: 211 year: 1991 end-page: 4 ident: CR24 article-title: Preclinical in vivo activity of 2’,2’-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer publication-title: Cancer Res – volume: 17 start-page: 120 year: 2018 end-page: 30 ident: CR43 article-title: Establishment and genetic landscape of precancer cell model systems from the head and neck mucosal lining publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-18-0445 – volume: 49 start-page: 560 year: 2013 end-page: 6 ident: CR48 article-title: Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2013.03.446 – volume: 668 start-page: 4 year: 2009 end-page: 10 ident: CR12 article-title: Fanconi anemia and its diagnosis publication-title: Mutat Res doi: 10.1016/j.mrfmmm.2009.01.013 – volume: 6 start-page: 92 year: 2020 ident: CR38 article-title: Head and neck squamous cell carcinoma publication-title: Nat Rev Dis Prim doi: 10.1038/s41572-020-00224-3 – volume: 7 start-page: 135 year: 2010 end-page: 7 ident: CR26 article-title: Gemcitabine remains the standard of care for pancreatic cancer publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2010.16 – volume: 42 start-page: E16 year: 2020 end-page: 22 ident: CR37 article-title: Successful use of a therapeutic trial of graduated volume and dose escalation for postoperative head and neck radiotherapy in a Fanconi anemia patient publication-title: Head Neck doi: 10.1002/hed.26395 – volume: 224 start-page: 132 year: 2012 end-page: 8 ident: CR3 article-title: Squamous cell carcinomas of the head and neck in Fanconi anemia: Risk, prevention, therapy, and the need for guidelines publication-title: Klin Padiatr doi: 10.1055/s-0032-1308989 – volume: 25 start-page: 94 year: 2019 end-page: 99 ident: CR40 article-title: Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation publication-title: Biol Blood Marrow Transpl doi: 10.1016/j.bbmt.2018.08.028 – volume: 25 start-page: 1286 year: 2004 end-page: 94 ident: CR20 article-title: Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine publication-title: J Comput Chem doi: 10.1002/jcc.20054 – volume: 41 start-page: 1418 year: 2019 end-page: 26 ident: CR36 article-title: Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: series of 9 cases and review of the literature publication-title: Head Neck doi: 10.1002/hed.25577 – volume: 23 start-page: 5225 year: 2017 end-page: 37 ident: CR16 article-title: Ribonucleotide reductase catalytic subunit M1 (RRM1) as a novel therapeutic target in multiple myeloma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0263 – volume: 3 start-page: 840 year: 2017 end-page: 56 ident: CR27 article-title: Fanconi anemia signaling and cancer publication-title: Trends Cancer doi: 10.1016/j.trecan.2017.10.005 – volume: 34 start-page: 2011 year: 2015 end-page: 21 ident: CR15 article-title: Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies publication-title: Oncogene doi: 10.1038/onc.2014.155 – volume: 62 start-page: 4757 year: 2002 end-page: 66 ident: CR45 article-title: Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine publication-title: Cancer Res – volume: 8 start-page: 1 year: 2017 end-page: 13 ident: CR49 article-title: Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck publication-title: Oncotarget – volume: 38 start-page: 567 year: 1990 end-page: 72 ident: CR19 article-title: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2’,2’-difluorodeoxycytidine publication-title: Mol Pharm – volume: 19 start-page: 188 year: 2007 end-page: 94 ident: CR29 article-title: Individual patientsʼ data meta-analyses in head and neck cancer publication-title: Curr Opin Oncol doi: 10.1097/CCO.0b013e3280f01010 – ident: CR47 – volume: 148 start-page: 1022 year: 2022 end-page: 8 ident: CR10 article-title: Cetuximab-based vs carboplatin-based chemoradiotherapy for patients with head and neck cancer publication-title: JAMA Otolaryngol Head Neck Surg doi: 10.1001/jamaoto.2022.2791 – ident: CR14 – volume: 57 start-page: 3886 year: 1997 end-page: 9 ident: CR44 article-title: Inappropriate retinoic acid receptor-β expression in oral dysplasias: correlation with acquisition of the immortal phenotype publication-title: Cancer Res – ident: CR2 – volume: 3 start-page: 447 year: 2008 end-page: 50 ident: CR41 article-title: Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with fanconi anemia publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318165c170 – volume: 125 start-page: 35 year: 2018 end-page: 40 ident: CR11 article-title: Oral cancer in Fanconi anemia: review of 121 cases publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2018.02.013 – volume: 13 start-page: 8507 year: 2007 end-page: 15 ident: CR21 article-title: Understanding ribonucleotide reductase inactivation by gemcitabine publication-title: Chemistry doi: 10.1002/chem.200700260 – volume: 13 start-page: 2774 year: 2021 ident: CR30 article-title: Targeted treatment of head and neck (Pre)cancer: preclinical target identification and development of novel therapeutic applications publication-title: Cancers (Basel) doi: 10.3390/cancers13112774 – volume: 100 start-page: 1649 year: 2008 end-page: 53 ident: CR46 article-title: Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn366 – volume: 27 start-page: 5168 year: 2021 end-page: 87 ident: CR5 article-title: Treatment of fanconi anemia–associated head and neck cancer: opportunities to improve outcomes publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-1259 – volume: 92 start-page: 4 year: 2009 end-page: 14 ident: CR28 article-title: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients publication-title: Radiother Oncol doi: 10.1016/j.radonc.2009.04.014 – volume: 12 start-page: 1 year: 2021 end-page: 13 ident: CR39 article-title: Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma publication-title: Nat Commun doi: 10.1038/s41467-021-26472-9 – volume: 27 start-page: R986 year: 2017 end-page: 8 ident: CR1 article-title: Fanconi anemia pathway publication-title: Curr Biol doi: 10.1016/j.cub.2017.07.043 – volume: 50 start-page: 7420 year: 2022 end-page: 35 ident: CR25 article-title: Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine publication-title: Nucleic Acids Res doi: 10.1093/nar/gkac545 – ident: CR23 – volume: 475 start-page: 53 year: 2011 end-page: 59 ident: CR9 article-title: Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice publication-title: Nature doi: 10.1038/nature10192 – volume: 393 start-page: 40 year: 2019 end-page: 50 ident: CR35 article-title: Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(18)32779-X – volume: 15 start-page: 301 year: 2004 end-page: 6 ident: CR33 article-title: Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck publication-title: Ann Oncol doi: 10.1093/annonc/mdh071 – volume: 22 start-page: OF1 year: 2023 end-page: 17 ident: CR32 article-title: ORAOV1, CCND1, and MIR548K are the driver oncogenes of the 11q13 amplicon in squamous cell carcinoma publication-title: Mol Cancer Res – volume: 101 start-page: 822 year: 2003 end-page: 6 ident: CR4 article-title: Cancer incidence in persons with Fanconi anemia publication-title: Blood doi: 10.1182/blood-2002-05-1498 – volume: 18 start-page: 168 year: 2018 end-page: 85 ident: CR6 article-title: Fanconi anaemia and cancer: an intricate relationship publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.116 – volume: 18 start-page: 269 year: 2018 end-page: 82 ident: CR7 article-title: The molecular landscape of head and neck cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc.2018.11 – volume: 126 start-page: 870 year: 2016 end-page: 9 ident: CR8 article-title: Natural history and management of Fanconi anemia patients with head and neck cancer: a 10-year follow-up publication-title: Laryngoscope doi: 10.1002/lary.25726 – volume: 668 start-page: 4 year: 2009 ident: 525_CR12 publication-title: Mutat Res doi: 10.1016/j.mrfmmm.2009.01.013 – volume: 27 start-page: 5168 year: 2021 ident: 525_CR5 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-1259 – volume: 38 start-page: 567 year: 1990 ident: 525_CR19 publication-title: Mol Pharm – volume: 13 start-page: 2774 year: 2021 ident: 525_CR30 publication-title: Cancers (Basel) doi: 10.3390/cancers13112774 – volume: 18 start-page: 168 year: 2018 ident: 525_CR6 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.116 – ident: 525_CR47 doi: 10.1016/j.oraloncology.2019.09.004 – volume: 101 start-page: 1249 year: 2003 ident: 525_CR13 publication-title: Blood doi: 10.1182/blood-2002-07-2170 – volume: 19 start-page: 188 year: 2007 ident: 525_CR29 publication-title: Curr Opin Oncol doi: 10.1097/CCO.0b013e3280f01010 – ident: 525_CR23 doi: 10.1186/s40348-014-0009-8 – volume: 23 start-page: 5225 year: 2017 ident: 525_CR16 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0263 – volume: 148 start-page: 1022 year: 2022 ident: 525_CR10 publication-title: JAMA Otolaryngol Head Neck Surg doi: 10.1001/jamaoto.2022.2791 – volume: 51 start-page: 211 year: 1991 ident: 525_CR24 publication-title: Cancer Res – volume: 49 start-page: 560 year: 2013 ident: 525_CR48 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2013.03.446 – volume: 17 start-page: 120 year: 2018 ident: 525_CR43 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-18-0445 – volume: 101 start-page: 822 year: 2003 ident: 525_CR4 publication-title: Blood doi: 10.1182/blood-2002-05-1498 – volume: 13 start-page: 8507 year: 2007 ident: 525_CR21 publication-title: Chemistry doi: 10.1002/chem.200700260 – volume: 57 start-page: 3886 year: 1997 ident: 525_CR44 publication-title: Cancer Res – volume: 6 start-page: 92 year: 2020 ident: 525_CR38 publication-title: Nat Rev Dis Prim doi: 10.1038/s41572-020-00224-3 – volume: 27 start-page: R986 year: 2017 ident: 525_CR1 publication-title: Curr Biol doi: 10.1016/j.cub.2017.07.043 – volume: 34 start-page: 2011 year: 2015 ident: 525_CR15 publication-title: Oncogene doi: 10.1038/onc.2014.155 – volume: 48 start-page: 4024 year: 1988 ident: 525_CR17 publication-title: Cancer Res – volume: 22 start-page: OF1 year: 2023 ident: 525_CR32 publication-title: Mol Cancer Res doi: 10.1186/s12943-022-01695-6 – volume: 7 start-page: 135 year: 2010 ident: 525_CR26 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2010.16 – volume: 8 start-page: 1 year: 2017 ident: 525_CR49 publication-title: Oncotarget doi: 10.18632/oncotarget.17880 – ident: 525_CR2 – volume: 18 start-page: 269 year: 2018 ident: 525_CR7 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2018.11 – volume: 92 start-page: 4 year: 2009 ident: 525_CR28 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2009.04.014 – volume: 62 start-page: 4757 year: 2002 ident: 525_CR45 publication-title: Cancer Res – volume: 393 start-page: 40 year: 2019 ident: 525_CR35 publication-title: Lancet doi: 10.1016/S0140-6736(18)32779-X – volume: 25 start-page: 1286 year: 2004 ident: 525_CR20 publication-title: J Comput Chem doi: 10.1002/jcc.20054 – volume: 15 start-page: 276 year: 2015 ident: 525_CR22 publication-title: Nat Rev Cancer doi: 10.1038/nrc3916 – volume: 3 start-page: 840 year: 2017 ident: 525_CR27 publication-title: Trends Cancer doi: 10.1016/j.trecan.2017.10.005 – volume: 475 start-page: 53 year: 2011 ident: 525_CR9 publication-title: Nature doi: 10.1038/nature10192 – volume: 126 start-page: 870 year: 2016 ident: 525_CR8 publication-title: Laryngoscope doi: 10.1002/lary.25726 – volume: 12 start-page: 1 year: 2021 ident: 525_CR39 publication-title: Nat Commun doi: 10.1038/s41467-021-26472-9 – volume: 393 start-page: 51 year: 2019 ident: 525_CR34 publication-title: Lancet doi: 10.1016/S0140-6736(18)32752-1 – volume: 42 start-page: E16 year: 2020 ident: 525_CR37 publication-title: Head Neck doi: 10.1002/hed.26395 – volume: 41 start-page: 1418 year: 2019 ident: 525_CR36 publication-title: Head Neck doi: 10.1002/hed.25577 – volume: 50 start-page: 7420 year: 2022 ident: 525_CR25 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkac545 – ident: 525_CR14 doi: 10.1038/s41598-020-58509-2 – volume: 51 start-page: 6110 year: 1991 ident: 525_CR18 publication-title: Cancer Res – volume: 100 start-page: 1649 year: 2008 ident: 525_CR46 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn366 – volume: 35 start-page: 568 year: 2013 ident: 525_CR42 publication-title: Head Neck doi: 10.1002/hed.23004 – volume: 25 start-page: 94 year: 2019 ident: 525_CR40 publication-title: Biol Blood Marrow Transpl doi: 10.1016/j.bbmt.2018.08.028 – volume: 125 start-page: 35 year: 2018 ident: 525_CR11 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2018.02.013 – volume: 15 start-page: 301 year: 2004 ident: 525_CR33 publication-title: Ann Oncol doi: 10.1093/annonc/mdh071 – volume: 97 start-page: 145 year: 2007 ident: 525_CR31 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603860 – volume: 224 start-page: 132 year: 2012 ident: 525_CR3 publication-title: Klin Padiatr doi: 10.1055/s-0032-1308989 – volume: 3 start-page: 447 year: 2008 ident: 525_CR41 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318165c170
SSID	ssj0000561655
Score	2.3191707
Snippet	Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of DNA... Abstract Fanconi anemia (FA) is a rare hereditary disease resulting from an inactivating mutation in the FA/BRCA pathway, critical for the effective repair of...
SourceID	doaj proquest pubmed crossref springer
SourceType	Open Website Aggregation Database Index Database Enrichment Source Publisher
StartPage	26
SubjectTerms	13 13/100 13/106 13/109 13/31 13/51 13/89 14 14/1 14/34 14/56 38 42 45 631/154/1438 631/154/555 631/154/556 631/208/68 631/67/1536 82 82/80 Anemia Apoptosis Breast cancer Cell Biology Chemoradiotherapy Chemotherapy Cisplatin DNA repair Fanconi syndrome Gemcitabine Genetic screening Head & neck cancer Head and neck carcinoma Hemopoiesis Hereditary diseases Human Genetics Internal Medicine Malignancy Medicine Medicine & Public Health Nucleotide analogs Oncology Patients Radiation therapy Ribonucleotide reductase siRNA Squamous cell carcinoma Therapeutic targets Toxicity Tumor cell lines
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1JixQxFA4yiHgRd8sZJYI3DVPZk6OKrQdtPCjMLWSFRrtaunoE__28pKrbEbeLt6KSKpLvvbylXuULQk-DlpEWIwgPIhARmSfe2kxYkF7p6mRL2yj8Ti-X5uzMfrh01Ff9J2yiB56AO_VcR6Vi8ZFnkbiyWYJFjcWCL7UxxGp9Ieq5lExNrN6KKinnXTI9N6ejqCU5Ai6J1E-hkrCfPFEj7P9dlPlLhbQ5nsVNdGOOGPGLaaS30JU83EbX3s818Tto-SavI2T4kOJm7EcMUljP26q-403BYG0T9kPCQ46fcaxS3uLVgBdwBQsamvJ65fFMsDreRZ8Wrz--ekvmUxJIFEbuCLWeKZb6FIqSTCRtbOHQEmkfeCgsZM94kQCZjpQVlS0NvS_ceJNTMJ7fQ0fDZsgPEDZChmB4EVYnEbUKvc6amVxo6SPVqUN0j5iLM4V4Pcnii2ulbG7chLIDlF1D2bEOPTs883Ui0Phr75dVEIeelfy63QCVcLNKuH-pRIdO9mJ084ocHdgyU6NNYzv05NAMa6kWSADpzXnrYyt9kFEduj-J_zCSykMI6XHfoed7ffjx8j9P6OH_mNAxus6a4mpC6Qk62m3P8yN0NX7brcbt46b5F67dBAM priority: 102 providerName: Directory of Open Access Journals
Title	Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients
URI	https://link.springer.com/article/10.1038/s41389-024-00525-2 https://www.ncbi.nlm.nih.gov/pubmed/38992100 https://www.proquest.com/docview/3078835289 https://www.proquest.com/docview/3079171686 https://doaj.org/article/a37c66cfac3e4d369e5284cf90649cbc
Volume	13
WOSCitedRecordID	wos001269120200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2157-9024 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000561655 issn: 2157-9024 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2157-9024 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000561655 issn: 2157-9024 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1di9QwcPD2RHzx-6N6LhF803BtkjbJk3iyq4K7LKKwPpUkTY5Ftz23e4Iv_naTbLaHqPfiy1A6aUk6n5lpZgCeaV6awgmGqWYaM0MUVlJaTHSpKh6MrIsHhd_z-Vwsl3KRAm59-q1yrxOjom46E2Lkx54XRfAWhHx59g2HrlEhu5paaBzAYahUxkZweDKZLz4MUZbgH1dlmU7L5FQc9yyk5rA3TTiEREtMfrNIsXD_37zNPzKl0QBNb_7v1G_BjeR6olc7XrkNV2x7B67NUnL9Lszf2LVZbZXfK1ukeuTJuU7ns36gziGvthuk2ga11nxBJrDLBq1aNPVXXjN4lF2vFEqVWvt78Gk6-fj6LU7tFrBhotziQipSkSZvtKtKwhoupKMeY4pcU-2ItopQVzLjuCmIq6wsdK4cFUrYRgtF78Oo7Vr7EJBgpdaCOiZ5wwyvdM4tJ8K6wuWm4E0Gxf6T1ybVIg8tMb7WMSdORb0jU-3JVEcy1SSD58MzZ7tKHJeOPgmUHEaGKtrxRrc5rZNQ1opyU1XGKUMta2glrSeSX5_0fpo02mRwtCdonUS7ry-omcHTAe2FMmRa_JfuzuMYGeoQiSqDBzv-GWYSChr6fXaewYs9Q128_N8LenT5XB7DdRJ5muOiOILRdnNun8BV83276jdjOOBLHqEYJxEZx-iDhzOyCJBH-HPi8Yt3s8XnX0CdGig
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qBQEX9iVQwEhwAqvxktg-IMQ2tOp0xKFIczO2Y6MRTKZMpqD-KX4jdpapENBbD9yS2LG8fG-xn997AE-sKBwJkmNmucXcUYONUh5TW5hSJCEbWkfhsZhM5HSqPmzAz8EXJl2rHHhiy6irhUtn5NsRizJpC1K9PPyGU9aoZF0dUmh0sNjzxz_ilq15sfs2ru9TSkfvDt7s4D6rAHZcFitMlKElrfLKhrKgvBJSBRZLHMkts4FabygLBXdBOEJD6RWxuQlMGukrKw2L7Z6D85GPi3SFTEzF-kwnaeNlUfS-OTmT2w1PhkAcBSFOB7AFpr_JvzZNwN902z_ssq24G1393ybqGlzpFWv0qqOE67Dh6xtwcb-_OnATJu_93M1WxsY3ZBoUwTrvvc-O0SKgKJQqZOoK1d59QS4RwxLNajSKT5HvxSI_nxnUx6FtbsHHMxnNbdisF7W_C0jywlrJAlei4k6UNhdeUOkDCbkjosqADEusXR9pPSX8-Kpbiz-TuoOFjrDQLSw0zeDZ-p_DLs7IqbVfJ-Ssa6YY4e2HxfKz7lmONky4snTBOOZ5xUrlIyji-FTUQpWzLoOtAUC6Z1yNPkFPBo_XxZHlJDtSnOnFUVtHpShLsszgTofXdU9SuEZK8jyD5wOATxr_94Dund6XR3Bp52B_rMe7k737cJm29CQwIVuwuVoe-QdwwX1fzZrlw5YgEXw6a2D_AkJXcBM
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qBVVc2JdAASPBCayJl8T2ASGgDFRtR3MAqTdjOzYawSRlMgX1r_HrsDPJVAjorQduSexEXr63xG8DeGJF4UiQHDPLLeaOGmyU8pjawpQiCdnQBQrvi8lEHh6q6Qb8HGJhklvlwBM7Rl01Lp2RjyIWZdIWpBqF3i1iujN-efQNpwpSydI6lNNYQWTPn_yIv2_ti92duNdPKR2__fDmPe4rDGDHZbHERBla0iqvbCgLyishVWCxxZHcMhuo9YayUHAXhCM0lF4Rm5vApJG-stKw-N0LcFHwokjUdUCn6_OdpJmXRdHH6eRMjlqejII4CkWcDmMLTH-ThV3JgL_puX_YaDvRN776Py_aNbjSK9zo1YpCrsOGr2_A1kHvUnATJu_83M2WxsY7ZFoUQTzvo9JOUBNQFFYVMnWFau--IJeIZIFmNRrHq8gPY5Ofzwzq89O2t-DjuczmNmzWTe3vApK8sFaywJWouBOlzYUXVPpAQu6IqDIgw3Zr12dgT4VAvurOE4BJvYKIjhDRHUQ0zeDZ-p2jVf6RM3u_Tiha90y5w7sHzeKz7lmRNky4snTBOOZ5xUrlI0Di_FTUTpWzLoPtAUy6Z2itPkVSBo_XzZEVJftSXOnmuOujUvYlWWZwZ4Xd9UhSGkdK8jyD5wOYTz_-7wndO3ssj2Ar4lnv70727sNl2pGWwIRsw-ZycewfwCX3fTlrFw872kTw6bxx_QugQnjg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gemcitabine+as+chemotherapy+of+head+and+neck+cancer+in+Fanconi+anemia+patients&rft.jtitle=Oncogenesis+%28New+York%2C+NY%29&rft.au=van+Harten%2C+Anne+M&rft.au=Shah%2C+Ronak&rft.au=de+Boer%2C+D.+Vicky&rft.au=Buijze%2C+Marijke&rft.date=2024-07-11&rft.pub=Nature+Publishing+Group&rft.eissn=2157-9024&rft.volume=13&rft.issue=1&rft.spage=26&rft_id=info:doi/10.1038%2Fs41389-024-00525-2&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2157-9024&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2157-9024&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2157-9024&client=summon